Journal Article

DKFZ-2025-00836

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png A German multicenter real-world analysis of talquetamab in 138 patients with relapsed/refractory multiple myeloma.

Frenking, J. H. (First author)DKFZ* ; Riedhammer, C. ; Teipel, R. ; Bassermann, F.DKFZ* ; Besemer, B. ; Bewarder, M. ; Braune, J. ; Brioli, A. ; Brunner, F. ; Dampmann, M. ; Fenk, R. ; Gezer, D. N. ; Goldman-Mazur, S. ; Hanoun, C. ; Högner, M. ; Khandanpour, C. ; Kolditz, K. ; Kos, I. ; Krönke, J.DKFZ* ; Kull, M. ; Landrin, V. ; Leitner, T. ; Merz, M. ; von Metzler, I. ; Michel, C. S. ; Müller-Tidow, C. ; Theurich, S.DKFZ* ; Trautmann-Grill, K. ; Wäsch, R. ; Zukovs, R. ; Hänel, M. ; Rasche, L. ; Raab, M.-S. (Last author)DKFZ*

2025
John Wiley & Sons Ltd. Hoboken

This record in other databases:  

Please use a persistent id in citations: doi:10.1002/hem3.70114

Abstract: Bispecific T-cell engagers (BTCEs) represent a paradigm shift in the treatment of relapsed/refractory multiple myeloma (RRMM). Talquetamab, a GPRC5DxCD3 BTCE, has shown promising results in the MonumenTAL-1 trial and was recently approved by the Food and Drug Administration and the European Medicines Agency. However, treatment under real-world conditions may not represent patient characteristics in clinical trials with restricted enrollment criteria. We performed a retrospective real-world analysis including 138 RRMM patients treated with talquetamab at 21 German centers. Of evaluable patients, 43% had ISS stage III, 37% had extraosseous disease, and 48% had high-risk cytogenetics. After a median of six prior therapy lines, 58% of patients would not have been eligible for MonumenTAL-1. With a median follow-up of 8.2 months, we observed an overall response rate of 65% and a median progression-free survival of 6.4 months (95% confidence interval 5.1-9.0). Prior BTCE exposure, ISS stage III, extraosseous disease, and penta-drug refractory disease were associated with unfavorable outcomes. Grade ≥ 3 cytokine release syndrome and neurotoxicity occurred in 5.1% and 1.5% of patients, respectively. In summary, our real-world study confirms the efficacy and safety of talquetamab, despite a high proportion of patient- and disease-related risk factors. These results support its use as bridging or long-term treatment, even in advanced stages.

Note: #EA:A360#LA:A360#

---

Contributing Institute(s):

1. KKE Mol. Hämatologie/Onkologie (A360)
2. DKTK Koordinierungsstelle München (MU01)
3. DKTK Koordinierungsstelle Berlin (BE01)

Research Program(s):

1. 311 - Zellbiologie und Tumorbiologie (POF4-311) (POF4-311)

Appears in the scientific report 2025

---

Database coverage:
; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DEAL Wiley ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---